Prosight Management, LP Adc Therapeutics Sa Transaction History
Prosight Management, LP
- $369 Million
- Q2 2025
A detailed history of Prosight Management, LP transactions in Adc Therapeutics Sa stock. As of the latest transaction made, Prosight Management, LP holds 10,467,771 shares of ADCT stock, worth $30.8 Million. This represents 7.6% of its overall portfolio holdings.
Number of Shares
10,467,771
Previous 9,543,004
9.69%
Holding current value
$30.8 Million
Previous $13.5 Million
108.49%
% of portfolio
7.6%
Previous 4.79%
Shares
12 transactions
Others Institutions Holding ADCT
# of Institutions
91Shares Held
67.9MCall Options Held
68.2KPut Options Held
75.8K-
Redmile Group, LLC San Francisco, CA15.7MShares$46.1 Million5.11% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct7.76MShares$22.8 Million0.05% of portfolio
-
Orbimed Advisors LLC San Diego, CA5.91MShares$17.4 Million0.57% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$10.5 Million0.0% of portfolio
-
Morgan Stanley New York, NY3.05MShares$8.95 Million0.0% of portfolio
About ADC Therapeutics SA
- Ticker ADCT
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,645,296
- Market Cap $228M
- Description
- ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...